After prostate-specific antigen (PSA) emerged, its use was immediately coupled with DRE to improve the detection of prostate cancer unfortunately this resulted in unnecessary earlier diagnosis and over treatment of patients with very low and low risk disease 3. This evidence concerns the gene KLK3 and Familial prostate cancer.